Cargando…

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs

BACKGROUND: Patients on dialysis often have secondary hyperparathyroidism (SHPT), a disorder associated with renal osteodystrophy, progressive vascular calcification, cardiovascular disease, and death. The objective of this retrospective observational study was to evaluate, in dialysis patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Roggeri, Alessandro, Conte, Ferruccio, Rossi, Carlotta, Cozzolino, Mario, Zocchetti, Carlo, Roggeri, Daniela Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111129/
https://www.ncbi.nlm.nih.gov/pubmed/32273898
http://dx.doi.org/10.7573/dic.2020-1-1
_version_ 1783513211832631296
author Roggeri, Alessandro
Conte, Ferruccio
Rossi, Carlotta
Cozzolino, Mario
Zocchetti, Carlo
Roggeri, Daniela Paola
author_facet Roggeri, Alessandro
Conte, Ferruccio
Rossi, Carlotta
Cozzolino, Mario
Zocchetti, Carlo
Roggeri, Daniela Paola
author_sort Roggeri, Alessandro
collection PubMed
description BACKGROUND: Patients on dialysis often have secondary hyperparathyroidism (SHPT), a disorder associated with renal osteodystrophy, progressive vascular calcification, cardiovascular disease, and death. The objective of this retrospective observational study was to evaluate, in dialysis patients with SHPT, the impact of different levels of adherence to cinacalcet therapy on hospitalisations and direct healthcare costs charged to the Lombardy Regional Health Service (Italy). METHODS: Data recorded in the administrative databases on all citizens undergoing dialysis between 1 January 2011 and 31 December 2011 were selected. For the aim of this study, patients with SHPT already on dialysis in the first 6 months of 2009 who had been treated with cinacalcet for at least 365 days were selected and retrospectively analysed through to end of 2012. Healthcare resource utilisation, cinacalcet adherence, and costs for medication, hospitalisations, and diagnostic/therapeutic procedures were estimated. RESULTS: A total of 994 patients were identified (mean age 63.0 years, females 43.5%). The first patient tertile had an adherence to cinacalcet of <64.1%, whereas the third had an adherence of over 91.5%. Patients in the third adherence tertile experienced fewer all-causes hospitalisations than those in the first tertile (−19.2%; p=0.01423), fractures (−37.1%; p=0.59422), cardiovascular disease (−23.8%; p=0.04025), and sepsis (−32.3%; p=0.01386). The increase in costs for cinacalcet-adherent patients is almost completely offset by the reduction in costs for hospitalisations. CONCLUSIONS: The results of the analysis suggest that there may be some correlation between a high level of cinacalcet adherence and a decrease in hospitalisations.
format Online
Article
Text
id pubmed-7111129
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-71111292020-04-09 Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs Roggeri, Alessandro Conte, Ferruccio Rossi, Carlotta Cozzolino, Mario Zocchetti, Carlo Roggeri, Daniela Paola Drugs Context Original Research BACKGROUND: Patients on dialysis often have secondary hyperparathyroidism (SHPT), a disorder associated with renal osteodystrophy, progressive vascular calcification, cardiovascular disease, and death. The objective of this retrospective observational study was to evaluate, in dialysis patients with SHPT, the impact of different levels of adherence to cinacalcet therapy on hospitalisations and direct healthcare costs charged to the Lombardy Regional Health Service (Italy). METHODS: Data recorded in the administrative databases on all citizens undergoing dialysis between 1 January 2011 and 31 December 2011 were selected. For the aim of this study, patients with SHPT already on dialysis in the first 6 months of 2009 who had been treated with cinacalcet for at least 365 days were selected and retrospectively analysed through to end of 2012. Healthcare resource utilisation, cinacalcet adherence, and costs for medication, hospitalisations, and diagnostic/therapeutic procedures were estimated. RESULTS: A total of 994 patients were identified (mean age 63.0 years, females 43.5%). The first patient tertile had an adherence to cinacalcet of <64.1%, whereas the third had an adherence of over 91.5%. Patients in the third adherence tertile experienced fewer all-causes hospitalisations than those in the first tertile (−19.2%; p=0.01423), fractures (−37.1%; p=0.59422), cardiovascular disease (−23.8%; p=0.04025), and sepsis (−32.3%; p=0.01386). The increase in costs for cinacalcet-adherent patients is almost completely offset by the reduction in costs for hospitalisations. CONCLUSIONS: The results of the analysis suggest that there may be some correlation between a high level of cinacalcet adherence and a decrease in hospitalisations. BioExcel Publishing Ltd 2020-03-27 /pmc/articles/PMC7111129/ /pubmed/32273898 http://dx.doi.org/10.7573/dic.2020-1-1 Text en Copyright © 2020 Roggeri A, Conte F, Rossi C, Cozzolino M, Zocchetti C, Roggeri DP. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Original Research
Roggeri, Alessandro
Conte, Ferruccio
Rossi, Carlotta
Cozzolino, Mario
Zocchetti, Carlo
Roggeri, Daniela Paola
Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
title Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
title_full Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
title_fullStr Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
title_full_unstemmed Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
title_short Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
title_sort cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in lombardy region: clinical implications and costs
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111129/
https://www.ncbi.nlm.nih.gov/pubmed/32273898
http://dx.doi.org/10.7573/dic.2020-1-1
work_keys_str_mv AT roggerialessandro cinacalcetadherenceindialysispatientswithsecondaryhyperparathyroidisminlombardyregionclinicalimplicationsandcosts
AT conteferruccio cinacalcetadherenceindialysispatientswithsecondaryhyperparathyroidisminlombardyregionclinicalimplicationsandcosts
AT rossicarlotta cinacalcetadherenceindialysispatientswithsecondaryhyperparathyroidisminlombardyregionclinicalimplicationsandcosts
AT cozzolinomario cinacalcetadherenceindialysispatientswithsecondaryhyperparathyroidisminlombardyregionclinicalimplicationsandcosts
AT zocchetticarlo cinacalcetadherenceindialysispatientswithsecondaryhyperparathyroidisminlombardyregionclinicalimplicationsandcosts
AT roggeridanielapaola cinacalcetadherenceindialysispatientswithsecondaryhyperparathyroidisminlombardyregionclinicalimplicationsandcosts